Quince Therapeutics, Inc. (IRLA): Operating Income
-$58.07M
Year ended 2025-12-31
-$127.16M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$58.07M | n/m | 2026-04-10, From 2025-01-01 |
| 2024-12-31 | -$57.28M | n/m | 2026-04-10, From 2024-01-01 |
| 2023-12-31 | -$34.62M | n/m | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | -$52.02M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$90.32M | n/m | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | -$78.89M | n/m | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | -$39.17M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$12.12M | n/a | 2021-03-01, From 2018-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (IRLA) | 2025-12-31 | -$58.07M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$77.63M | n/m |
| LeonaBio, Inc. (LONA) | 2025-12-31 | -$102.27M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$42.09M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | -$87.98M | n/m |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | -$51.41M | n/m |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$5.50M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | -$22.66M | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$36.62M | n/m |
Compare IRLA, ATYR, LONA, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗